Results 101 to 110 of about 769 (187)

Apalutamide-induced life-threatening dermatologic toxicity: Clinical histopathological correlations and salvage therapies in four cases: Case report series. [PDF]

Medicine (Baltimore)
Li Y, Cao Y, Wei L, Zhao J, Tao M, Zhao X.   +5 more
europepmc   +1 more source

Cancer-control outcomes of patients with metastatic hormone-sensitive prostate cancer and ≥ 10 bone metastases receiving apalutamide: a real-world cohort. [PDF]

BMC Cancer
Wenzel M, Filzmayer M, Siech C, Le QC, Lauer B, Theissen L, Hoeh B, Heinzer H, Graefen M, Steuber T, Kriegmair M, Chun FK, Mandel P.   +12 more
europepmc   +1 more source

A high eosinophil proportion increases the risk of skin-related adverse events induced by apalutamide in patients with prostate cancer. [PDF]

Front Immunol
Tasaki Y, Naiki T, Mimura Y, Sugiyama Y, Tomita M, Morikawa T, Nagai T, Unno R, Etani T, Hamamoto S, Umemoto Y, Yasui T, Furukawa-Hibi Y.   +12 more
europepmc   +1 more source

Association between medication burden and acute care use in older metastatic prostate cancer patients on androgen receptor signaling inhibitors. [PDF]

Cancer
Liu MA, Raghunathan R, Runcie K, Wooster M, Wang S, Wright JD, Wei AZ, Stein M, Hershman DL.   +8 more
europepmc   +1 more source

The Therapeutic Potential of Spirooxindoles in Cancer: A Focus on p53-MDM2 Modulation. [PDF]

Pharmaceuticals (Basel)
Girgis AS, Zhao Y, Nkosi A, Ismail NSM, Bekheit MS, Aboshouk DR, Aziz MN, Youssef MA, Panda SS.   +8 more
europepmc   +1 more source

The impact of concomitant therapies on the efficacy and safety of relugolix in advanced prostate cancer. [PDF]

Future Oncol
Shore ND, George DJ, Spratt DE, De La Cerda J.   +3 more
europepmc   +1 more source

Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer in Japan: The ARASHI Study. [PDF]

Int J Urol
Suzuki K, Khan N, Taguchi T, Hattori K, Chen G, Ghadessi M, Constantinovici N, Quintero V, Suzuki H.   +8 more
europepmc   +1 more source

Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studies. [PDF]

Future Oncol
Karsh LI, Bevans KB, Saad F, Chung BH, Oudard S, Brookman-May SD, McCarthy SA, Smith MR, Chi KN, Small EJ, Agarwal N.   +10 more
europepmc   +1 more source

Comparative real-world study of apalutamide and darolutamide in Japanese patients with non-metastatic castration-resistant prostate cancer. [PDF]

BMC Urol
Ikeda M, Uemura K, Ito Y, Ito H, Kawahara T, Hasumi H, Teranishi JI, Makiyama K, Uemura H.   +8 more
europepmc   +1 more source

Comparative effectiveness of androgen receptor pathway inhibitor treatment intensification for metastatic hormone-sensitive prostate cancer in real-world patients. [PDF]

Investig Clin Urol
Lee CH, Kim S, Ku JY, Kim KH, Kang BJ, Goh HJ, Seo WI, Ha HK.   +7 more
europepmc   +1 more source